Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia

Critical Care Medicine

Volumn 32, Issue 6, 2004, Pages 1332-1337

  Lalu, Manoj M ^a   Csont, Tamás ^a   Schulz, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Endotoxemia; Matrix metalloproteinases; Myocardium; Plasma

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; GELATIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; PYROGEN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENDOTOXEMIA; ENZYME ACTIVITY; HEMOCONCENTRATION; INJECTION; MALE; MEDICAL RESEARCH; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RAT; STATISTICAL SIGNIFICANCE; SYMPTOM; UNIVERSITY; ZYMOGRAPHY;

ANIMALS; BLOOD PRESSURE; ENDOTOXEMIA; IMMUNOBLOTTING; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MYOCARDIUM; PROSPECTIVE STUDIES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS;

EID: 2942528804     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000127778.16609.EC     Document Type: Article

References (39)

1. Calandra T, Echtenacher B, Le Roy D, et al: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6:164-170
2. Kilbourn RG, Traber DL, Szabo C: Nitric oxide and shock. Dis Mon 1997; 43:277-348
3. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: The good the bad, and the ugly. Am J Physiol Cell Physiol 1996; 271:C1424-C1437
4. Kooy NW, Lewis SJ, Royall JA, et al: Extensive tyrosine nitration in human myocardial inflammation: Evidence for the presence of peroxynitrite. Crit Care Med 1997; 25:812-819
5. Kooy NW, Royall JA, Ye YZ, et al: Evidence for in vivo peroxynitrite production in human acute lung injury. Am J Respir Crit Care Med 1995; 151:1250-1254
6. Kamisaki Y, Wada K, Ataka M, et al: Lipopolysaccharide-induced increase in plasma nitrotyrosine concentrations in rats. Biochim Biophys Acta 1997; 1362:24-28
7. Kilbourn RG, Szabo C, Traber DL: Beneficial vs. detrimental effects of nitric oxide synthase inhibitors in circulatory shock: Lessons learned from experimental and clinical studies. Shock 1997; 7:235-246
8. Woessner JF: The matrix metalloproteinase family. In: Matrix Metalloproteinases. Parks W, Mecham R (Eds). San Diego, CA, Academic Press, 1998, pp 1-14
9. Gunasinghe HR, Coker ML, Thorp AJ, et al: Increased matrix metalloproteinase plasma concentrations in patients with congestive heart failure: Relation to cytokine activation. Abstr. Circulation 2000; 102:II403-II404
10. Tyagi SC, Ratajska A, Weber KT: Myocardial matrix metalloproteinase(s): Localization and activation. Mol Cell Biochem 1993; 126:49-59
11. Spinale FG, Coker ML, Heung LJ, et al: A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102:1944-1949
12. Rohde LE, Ducharme A, Arroyo LH, et al: Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999; 99:3063-3070
13. Blankenberg S, Rupprecht HJ, Poirier O, et al: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107:1579-1585
14. Cheung P-Y, Sawicki G, Wozniak M, et al: Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101:1833-1839
15. Wang W, Schulze CJ, Suarez-Pinzon WL, et al: Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106:1543-1549
16. Okamoto T, Akaike T, Sawa T, et al: Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 2001; 276:29596-29602
17. Rajagopalan S, Meng XP, Ramasamy S, et al: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98:2572-2579
18. Wang W, Sawicki G, Schulz R: Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 2002; 53:165-174
19. Khadour FH, Panas D, Ferdinandy P, et al: Enhanced NO and superoxide generation in dysfunctional hearts from endotoxemic rats. Am J Physiol Heart Circ Physiol 2002; 283:H1108-H1115
20. Pagenstecher A, Stalder AK, Kincaid CL, et al: Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice. Am J Pathol 2000; 157:197-210
21. Pagenstecher A, Stalder AK, Campbell IL: RNAse protection assays for the simultaneous and semiquantitative analysis of multiple murine matrix metalloproteinase (MMP) and MMP inhibitor mRNAs. J Immunol Methods 1997; 206:1-9
22. Dubois B, Starckx S, Pagenstecher A, et al: Gelatinase B deficiency protects against endotoxin shock. Eur J Immunol 2002; 32:2163-2171
23. Carney DE, McCann UG, Schiller HJ, et al: Metalloproteinase inhibition prevents acute respiratory distress syndrome. J Surg Res 2001; 99:245-252
24. Guide to the Care and Use of Laboratory Animals. Canadian Council on Animal Care, 1993
25. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992; 105:575-580
26. Green LC, Wagner DA, Glogowski J, et al: Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982; 126:131-138
27. Heussen C, Dowdle EB: Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102:196-202
28. Deleted in proof
29. Carnes CA, Chung MK, Nakayama T, et al: Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001; 89:E32-E38
30. Kjeldsen L, Johnsen AH, Sengelov H, et al: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993; 268:10425-10432
31. Groeneveld PH, Kwappenberg KM, Langermans JA, et al: Nitric oxide (NO) production correlates with renal insufficiency and multiple organ dysfunction syndrome in severe sepsis. Intensive Care Med 1996; 22:1197-1202
32. Xie B, Dong Z, Fidler IJ: Regulatory mechanisms for the expression of type IV collagenases/gelatinases in murine macrophages. J Immunol 1994; 152:3637-3644
33. Kim H, Koh G: Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2000; 269:401-405
34. Qun Gao C, Sawicki G, Suarez-Pinzon WL, et al: Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 2003; 57:426-433
35. Nakamura T, Ebihara I, Shimada N, et al: Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA concentrations in patients with septic shock: Effect of fiber-immobilized polymyxin B treatment. Am J Med Sci 1998; 316:355-360
36. Albert J, Radomski A, Soop A, et al: Differential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers. Acta Anaesthesiol Scand 2003; 47:407-410
37. Noble LJ, Donovan F, Igarashi T, et al: Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 2002; 22:7526-7535
38. Witte J, Jochum M, Scherer R, et al: Disturbances of selected plasma proteins in hyperdynamic septic shock. Intensive Care Med 1982; 8:215-222
39. Balduyck M, Albani D, Jourdain M, et al: Inflammation-induced systemic proteolysis of inter-alpha-inhibitor in plasma from patients with sepsis. J Lab Clin Med 2000; 135:188-198